Blog Detail

AMFI-Registered Mutual Fund Distributor

Home / Blog / IPO EMCURE PHARMACEUTICALS LIMITED

EMCURE PHARMACEUTICALS LIMITED

  July 3,2024
As the 13th largest pharmaceutical company in India by Domestic Sales for MAT FY24 and the 4th largest by market share in Covered Markets, Emcure has a diverse product portfolio that includes orals, injectables, and biotherapeutics, focusing on chronic therapeutic areas. Emcure leads in the gynecology and HIV antivirals sectors with a market share of 13.53% in gynecology, outperforming the nearest competitor by 1.70 times. With a global footprint, the company has filed over 1,800 dossiers, including 209 in the EU and 142 in Canada, and holds 220 patents. The company operates 13 manufacturing facilities across India, producing a wide range of pharmaceutical products.
More facts on Emcure Pharmaceuticals Ltd:
❖Well-placed to leverage its position in the domestic market
❖Large, diversified and fast-growing product portfolio in international markets
❖Strong R&D capabilities driving differentiated portfolio of products with extensive and diversified manufacturing capacity
 
Interested in applying? Get back to us

Tags : ,

Visit counter For Websites